4D Molecular Therapeutics (FDMT) Return on Capital Employed Growth (3y) (2024 - 2026)

4D Molecular Therapeutics (FDMT) Return on Capital Employed Growth (3y) (2024 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 4,893.00
4 NuCana 279.75 Bn 279.75 Bn - 2,416.00
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -494.00
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -649.00
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -3,782.00
10 4D Molecular Therapeutics 706.51 Mn 315.62 Mn - 1,090.00

Historic Data

Download Data
DateValue
Mar 31, 2026 1,090.00
Dec 31, 2025 776.00
Sep 30, 2025 -1,780.00
Jun 30, 2025 -1,377.00
Mar 31, 2025 -1,489.00
Dec 31, 2024 -855.00
Sep 30, 2024 -56.00
Jun 30, 2024 -103.00
Mar 31, 2024 -330.00